<DOC>
	<DOCNO>NCT01016366</DOCNO>
	<brief_summary>The primary purpose study determine whether carbamylated erythropoietin safe treatment patient suffer Friedreich 's Ataxia .</brief_summary>
	<brief_title>Safety Study Carbamylated Erythropoietin Treat Patients With Neurodegenerative Disorder Friedreich 's Ataxia</brief_title>
	<detailed_description>Friedreich 's Ataxia ( FRDA ) hereditary , progressive neurodegenerative disorder cause mutation gene encode frataxin . The mutation result severe reduction level mitochondrial protein , frataxin . A decline frataxin level associate consequence believe primary cause symptom FRDA patient . The clinical symptom FRDA include progressive gait limb ataxia , dysarthria , diabetes mellitus hypertrophic cardiomyopathy . First symptoms usually appear age 5 15 year . As disease progress patient becomes confine wheel chair later stag patient become increasingly incapacitated . There currently effective treatment FRDA . The naturally occur hormone , erythropoietin ( EPO ) , able protect various neuronal tissue ischemic injury . Recombinant human erythropoietin ( EPO ) increase frataxin expression lymphocytes patient FRDA . Also , EPO treatment FRDA patient result favourable outcome compare baseline assess level frataxin biomarkers oxidative stress . In pilot study EPO FRDA patient , treatment well tolerate apart expect haematological ( haematopoietic ) side effect . Lu AA24493 ( CEPO ) modify ( carbamylated ) version EPO , neuroprotective without haematopoietic side effect . Lu AA24493 develop treatment patient FRDA . Although target non-haematological effect Lu AA24493 ( EPO ) currently unknown , Lu AA24493 ( CEPO ) protect cell tissue various type injury . Furthermore , vitro Lu AA24493 ( CEPO ) increase frataxin level lymphocytes FRDA patient well control patient . This study aim evaluate safety 2 week treatment ( 6 dos , 3 dos per week ) CEPO patient FRDA explore efficacy use neurological rating scale explore level frataxin biomarkers oxidative stress .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>The patient diagnose FRDA genetic test demonstrating &gt; 400 GAA nucleotide triplet repeat shorter two frataxin alleles The patient SARA ( Stance ) subscore &lt; =6 The patient SARA ( Gait ) subscore &lt; =6 Man woman , age 18 year If female woman agree try become pregnant study , use adequate protection/abstinence child bear potential Clinically significant unstable illness liver , kidney , heart , stomach problem unrelated disease FRDA Disallowed medication Serious underlie disease Clinically significant abnormal vital sign unrelated underlying disease FRDA Abnormal laboratory blood result consider doctor clinically significant , e.g.anaemia Treatment idebenone within 6 week prior screen Treatment erythropoietin within 16 week prior screen Clinically significant abnormal ECG Received donate blood within previous 3 month Participation within another clinical trial within past 30 day Pregnancy breast feeding History drug allergy hypersensitivities Current ( within past 6 month ) disorder relate drug alcohol abuse ( define DSMIVTR )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Friedreich 's Ataxia</keyword>
	<keyword>FRDA</keyword>
	<keyword>Neurodegenerative</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Carbamylated</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Frataxin</keyword>
</DOC>